Douglas Wesley Brenneman

US Patent:

7427590, Sep 23, 2008

Filed:

Sep 12, 2002

Appl. No.:

10/489515

Inventors:

Douglas E. Brenneman - North Wales PA, US
Raquel Castellon - Norwalk CA, US
Catherine Y. Spong - Arlington VA, US
Janet M. Hauser - Bethesda MD, US
Illana Gozes - Ramat Hasharon, IL

Assignee:

The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
Ramot at Tel-Aviv University, Ltd. - Tel Aviv

International Classification:

A61K 38/03
A61K 38/04
A61K 38/08
A61K 38/10
C07K 4/12
C07K 7/06
C07K 7/08

US Classification:

514 2, 514 13, 514 15, 530300, 530323, 530326, 530328

Abstract:

This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

US Patent:

8609849, Dec 17, 2013

Filed:

Nov 29, 2011

Appl. No.:

13/306103

Inventors:

Garry Robert Smith - Royersford PA, US
Douglas E. Brenneman - North Wales PA, US
Allen B. Reitz - Lansdale PA, US
Yan Zhang - Fort Washington PA, US
Yanming Du - Cheshire CT, US

Assignee:

Fox Chase Chemical Diversity Center, Inc. - Doylestown PA
Advanced Neural Dynamics, Inc. - Doylestown PA

International Classification:

C07D 211/52
C07C 307/06
A61K 31/451
A61K 31/18

US Classification:

546217, 564 79, 514379, 514600

Abstract:

Pharmaceutical compositions of the invention include hydroxylated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.

US Patent:

20040235747, Nov 25, 2004

Filed:

Dec 29, 2003

Appl. No.:

10/748765

Inventors:

Illana Gozes - Ramat-Hasharon, IL
Daniel Offen - Kfar Haroeh, IL
Eliezer Giladi - Netania, IL
Eldad Melamed - Tel-Aviv, IL
Douglas Brenneman - North Wales PA, US

International Classification:

A61K038/10

US Classification:

514/014000

Abstract:

The present invention provides methods for preventing and/or treating autoimmune diseases, including multiple sclerosis, in a subject using ADNF polypeptides, by treating the subject with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide.

US Patent:

20090124543, May 14, 2009

Filed:

Aug 13, 2007

Appl. No.:

11/838128

Inventors:

Illana Gozes - Ramat Hasharon, IL
Douglas E. Brenneman - North Wales PA, US
Merav Bassan - Givat-Poleg, IL
Rachel Zamostiano - Hod-Hasharon, IL

Assignee:

The Govt. of the U.S.A., as represented by the Secretary of the Dept. of Health & Human Services - Rockville MD
Ramot at Tel-Aviv University Ltd. - Tel Aviv

International Classification:

A61K 38/17
C12N 5/00
A61P 25/28
A61P 25/16
A61P 25/00

US Classification:

514 12, 435377

Abstract:

The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.

US Patent:

20090247457, Oct 1, 2009

Filed:

Aug 25, 2008

Appl. No.:

12/197915

Inventors:

DOUGLAS E. BRENNEMAN - NORTH WALES PA, US
RAQUEL CASTELLON - NORWALK CA, US
CATHERINE Y. SPONG - ARLINGTON VA, US
JANET M. HAUSER - BETHESDA MD, US
IIIANA GOZES - RAMAT-HASHARON, IL

Assignee:

SECRETARY OF THE DEPTARTMENT OF HEALTH AND HUMAN SERVICES - ROCKVILLE MD
RAMOT AT TEL-AVIV UNIVERSITY - TEL AVIV

International Classification:

A61K 38/17
C12N 5/00
A61K 38/10
A61K 38/08
A61P 25/28
A61P 25/32
A61P 15/00
A61P 25/00

US Classification:

514 12, 435377, 514 13, 514 15, 514 14

Abstract:

This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

US Patent:

20120302546, Nov 29, 2012

Filed:

Feb 3, 2011

Appl. No.:

13/576556

Inventors:

Garry Robert Smith - Royersford PA, US
Douglas Eric Brenneman - North Wales PA, US
Allen B. Reitz - Lansdale PA, US
Yanming Du - Cheshire CT, US

Assignee:

FOX CHASE CHEMICAL DIVERSITY CENTER, INC. - Doylestown PA
ADVANCED NEURAL DYNAMICS, INC. - Doylestown PA

International Classification:

C07C 307/06
A61P 25/28
A61K 31/397
C07D 333/58
A61K 31/381
C07D 409/04
A61K 31/16
A61P 25/08

US Classification:

51421019, 564 79, 514600, 549 58, 514443, 548952

Abstract:

Pharmaceutical compositions of the invention include sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, and any neurodegenerative disease involving glutamate toxicity.

US Patent:

20130253022, Sep 26, 2013

Filed:

Nov 18, 2011

Appl. No.:

13/990630

Inventors:

Garry Robert Smith - Royersford PA, US
Douglas E. Brenneman - North Wales PA, US
Allen B. Reitz - Lansdale PA, US
Yan Zhang - Fort Washington PA, US
Yanming Du - Cheshire CT, US

Assignee:

FOX CHASE CHEMICAL DIVERSITY CENTER, INC. - Doylestown PA
ADVANCED NEURAL DYNAMICS, INC. - Doylestown PA

International Classification:

C07C 307/06
C07D 261/20
C07D 333/58

US Classification:

514379, 564 79, 514600, 549 58, 514443, 548241

Abstract:

Pharmaceutical compositions of the invention include fluorinated sulfamide derivatives having a disease-modifying action in the treatment of diseases associated with excitotoxicity and accompanying oxidative stress that include epilepsy, Alzheimer's disease, Parkinson's disease, Huntington's disease, heavy metal toxicity and any neurodegenerative disease involving glutamate toxicity.